Yoshitaka Sekine
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
前立腺癌に対するPARP阻害剤・スタチン・プラチナ製剤併用効果の基礎的研究
Open Date: 2019-04-01
Close Date: 2022-03-31
Grant: Close
Combination therapy with X-ray or heavy ion therapy and statin for prostate cancer
Open Date: 2016-04-01
Close Date: 2019-03-31
Grant: Close
Lipid and steroid metabolism and prostate cancer using imaging mass-spectrometry
Open Date: 2015-04-01
Close Date: 2018-03-31
Grant: Close
Effect of statins on de novo steroid synthesis pathways in androgen independent prostate cancer cells.
Open Date: 2013-04-01
Close Date: 2015-03-31
Grant: Close
The role of lipid metabolism in prostate cancer
Open Date: 2011-04-01
Close Date: 2014-03-31
Articles (11)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Introduction Acquired factor V (FV) deficiency is a rare bleeding disorder requiring careful management, especially in hemodialysis (HD) patients who regularly receive anticoagulants. We present a case of recurrent acquired FV deficiency in a dialysis patient. Case Presentation A 76‐year‐old man on HD with a history of acquired FV deficiency developed third‐degree burns and persistent bleeding. Lab tests confirmed the recurrence of the deficiency. Initial treatments with rituximab and cyclophosphamide were ineffective. When prednisolone was rechallenged, the activity of coagulation FV was rapidly improved, and coagulation function was confirmed to have returned to normal. HD was managed without anticoagulants during critical periods. No major bleeding events were observed during HD. Conclusion This case underscores the complexities of managing acquired FV deficiency in patients on HD. It highlights the importance of individualized anticoagulation strategies and close monitoring of coagulation profiles to prevent bleeding complications and ensure the safety of HD.
Year:
2026
Year:
2026
Introduction Intramural ureteral urothelial carcinoma can be difficult to diagnose, especially when presenting without mucosal abnormalities or positive cytology. In such cases, percutaneous biopsy may provide an alternative diagnostic approach. Case Presentation A 74‐year‐old man presented with acute renal failure caused by bilateral hydronephrosis. Cystoscopy showed no mucosal abnormality. Retrograde pyeloureterography revealed bilateral distal ureteral strictures, but urine cytology from ureteral catheters was negative. Imaging revealed a submucosal mass on the right dorsal bladder wall. Urothelial carcinoma was diagnosed on a computed tomography‐guided percutaneous trans‐extraperitoneal and transvesical biopsy. Neoadjuvant chemotherapy was administered and radical cystectomy performed. Pathology confirmed invasive urothelial carcinoma originating from the right intramural ureter at the ureterovesical junction with bladder muscle invasion. Conclusion This case highlights the diagnostic challenges of intramural ureteral urothelial carcinoma presenting as a submucosal bladder tumor. Computed tomography‐guided percutaneous biopsy can be a safe and effective diagnostic option in such challenging cases.
Year:
2026
Objective In this study, we compared the prostate health index (PHI) and the Prostate Imaging Reporting and Data System (PI‐RADS) before prostate biopsy and evaluated the utility of combining them in the diagnosis of prostate cancer (PC). Methods Between November 2021 and March 2023, 105 patients admitted to Gunma University Hospital for prostate biopsy after undergoing both MRI and PHI measurements were enrolled in this study. We investigated the diagnostic impacts of [−2]proPSA related indexes on clinically significant PC (csPC) and the complementary effects of PHI and PI‐RADS. Results The median of PHI was 59.9, and 72 patients (69%) were diagnosed with PC. The receiver operating characteristic (ROC) curve for patients diagnosed with PC indicated an area under the curve (AUC) of 0.816 for PHI and 0.753 for PI‐RADS. For PHI, when the sensitivity was 90% and 95%, the specificity was 51.5% and 45.5%, respectively. Both are higher than those of the conventional PSA‐related indices. In addition, the ROC curve in patients with a diagnosis of csPC ( n = 67) indicated an AUC of 0.793 for PHI and 0.746 for PI‐RADS. Furthermore, if biopsy was restricted to patients with PI‐RADS ≥ 4 or PHI ≥ 38.1, 21% of unnecessary biopsies could be avoided, with only one (1.5%) patient with csPC being missed. Conclusions PHI is more available for detecting csPC than PSA and PSA F/T. Moreover, there is a possibility that unnecessary prostate biopsies can be avoided by combining PHI and PI‐RADS.
Year:
2025
Year:
2025
Year:
2023
Collaborators (5)
Yoshiyuki Miyazawa
Assistant Professor
Gunma University
Seiji Arai
Gunma University
Masaki Shiota
Kyushu University
Takuma Kato
Kagawa University
Mikio Sugimoto
Professor
Kagawa University
Make your next move.
Prepare your application
Review drafts before you send them.